The possible role of
poly(C)
RNase serum activity and CEA serum level for early detection and differentiation of
pancreatic carcinoma and its specificity and valuability were critically analyzed: Serum
RNase (median, min-max) with polycytidin as substrate was determined in 13 "normal" patients (14.6 E/ml, 4.3--29.8 E/ml), 16 patients with
pancreatic cancer (T3 or
metastases) (17.6 E/ml, 6--49-9 E/ml), 15 patients with
chronic pancreatitis (9.5 E/ml, 4.9--26.5 E/
ml), 7 patients with
acute pancreatitis (14.2 E/ml, 5.5--67.3 ng/ml), and 13 patients with other types of malignomas (15 E/ml, 4.3--42.5 E/ml). Serum CEA level was evaluated in 18 "normal" patients (1.15 ng/ml, 0--4.3 ng/ml), 12 patients with
pancreatic carcinoma (T3 or
metastases) (6.5 mg/ml, 2--456.5 ng/ml), 13 patients with
chronic pancreatitis (2.3 ng/ml, 0--8.5 ng/ml), 8 patients with
acute pancreatitis (2.7 ng/ml, 0.1--4.6 ng/ml) and 5 patients without operative verification of suspected
pancreatic carcinoma (0.9 ng/ml, 0--1.7 ng/ml). The serum
RNase activity in
pancreatic cancer patients did not show any significant increase in comparison to the other groups, and these patients could not be distinguished from those with the other diseases when excluding other factors influencing serum
RNase level such as:
Renal insufficiency, nutrition, age, sex. Their CEA level was significantly higher in comparison to the other groups (p less than 0.05). Using 2.5 ng/ml as the limit, the sensitivity was found to be 80% (10/12 of
pancreatic carcinomas positive) and the specificity being 70.5% (31/44 of other groups without malignant diseases negative). The presented study and data in the literature show that
poly (C)
RNase measurement is not useful in early detection of
pancreatic carcinoma, but the CEA test could be helpful in the differential diagnosis of
pancreatic diseases due to its specificity (70.5%) and seems to be valuable in detection of residual and in monitoring for recurrent
pancreatic carcinoma in view of its sensitivity and correlation with the stage of
cancer.